Phenotypic CYP2A6 variation and the risk of pancreatic cancer

Journal of the Pancreas

Volumn 10, Issue 3, 2009, Pages 263-270

  Kadlubar, Susan ^a   Anderson, Jeffrey P ^b   Sweeney, Carol ^c   Gross, Myron D ^d   Lang, Nicholas P ^e   Kadlubar, Fred F ^a   Anderson, Kristin E ^f  

^a UNIVERSITY OF ARKANSAS FOR MEDICAL SCIENCES   (United States)

^b HARVARD SCHOOL OF PUBLIC HEALTH   (United States)

^c UNIVERSITY OF UTAH SCHOOL OF MEDICINE   (United States)

^d UNIVERSITY OF MINNESOTA MEDICAL SCHOOL   (United States)

^e UNIVERSITY OF ARKANSAS FOR MEDICAL SCIENCES   (United States)

^f UNIVERSITY OF MINNESOTA   (United States)

Author keywords

Coumarin 7 hydroxylase; Nitrosamines; Pancreatic neoplasms; Risk

Indexed keywords

CAFFEINE; CYTOCHROME P450 2A6; CARCINOGEN; COUMARIN 7 HYDROXYLASE; COUMARIN 7-HYDROXYLASE; UNSPECIFIC MONOOXYGENASE;

ACADEMIC ACHIEVEMENT; ADULT; AGED; ARTICLE; CANCER RISK; CARCINOGENICITY; CIGARETTE SMOKING; CONTROLLED STUDY; DEMOGRAPHY; DIABETES MELLITUS; DIETARY INTAKE; ENZYME ACTIVITY; FEMALE; FOOD INTAKE; GENETIC VARIABILITY; HUMAN; MAJOR CLINICAL STUDY; MALE; MEAT; PANCREAS CANCER; PHENOTYPE; SMOKING; CASE CONTROL STUDY; ENZYME ACTIVATION; GENETIC PREDISPOSITION; GENETICS; METABOLISM; MIDDLE AGED; PANCREAS TUMOR; RISK FACTOR; UNITED STATES;

ADULT; AGED; AGED, 80 AND OVER; ARYL HYDROCARBON HYDROXYLASES; CAFFEINE; CARCINOGENS; CASE-CONTROL STUDIES; ENZYME ACTIVATION; FEMALE; GENETIC PREDISPOSITION TO DISEASE; HUMANS; MALE; MEAT; MIDDLE AGED; MIDWESTERN UNITED STATES; PANCREATIC NEOPLASMS; PHENOTYPE; RISK FACTORS; SMOKING; YOUNG ADULT;

EID: 68149137266     PISSN: None     EISSN: 15908577     Source Type: Journal    
DOI: None     Document Type: Article

References (45)

1. American Cancer Society. Cancer Facts and Figures, 2008. Atlanta, GA, USA: American Cancer Society, 2008.
2. Anderson KE, Sinha R, Kulldorff M, Gross M, Lang NP, Barber C, et al. Meat intake and cooking techniques: associations with pancreatic cancer. Mutat Res 2002; 506-507:225-31.
3. Stolzenberg-Solomon RZ, Cross AJ, Silverman DT, Schairer C, Thompson FE, Kipnis V, et al. Meat and meat-mutagen intake and pancreatic cancer risk in the NIH-AARP Cohort. Cancer Epidemiol Biomarkers Prev 2007; 16:2664-75.
4. Risch HA. Etiology of pancreatic cancer, with a hypothesis concerning the role of N-nitroso compounds and excess gastric acidity. J Natl Cancer Inst 2003; 95:948-60.
5. Anderson KE, Mack T, Silverman D. Cancer of the Pancreas. In: Schottenfeld D, Fraumeni JF Jr, eds Cancer Epidemiology and Prevention New York, NY, USA: Oxford University Press, 2006:721-62.
6. Oscarson M. Genetic polymorphisms in the cytochrome P450 2A6 (CYP2A6) gene: implications for interindividual differences in nicotine metabolism. Drug Metab Dispos 2001; 29:91-5.
7. Pelkonen O, Rautio A, Raunio H, Pasanen M. CYP2A6: a human coumarin 7-hydroxylase. Toxicology 2000; 144:139-47.
8. Fujita K, Kamataki T. Predicting the mutagenicity of tobacco-related N-nitrosamines in humans using 11 strains of Salmonella typhimurium YG7108, each coexpressing a form of human cytochrome P450 along with NADPH-cytochrome P450 reductase. Environ Mol Mutagen 2001; 38:339-46.
9. Xu C, Goodz S, Sellers EM, Tyndale RF. CYP2A6 genetic variation and potential consequences. Adv Drug Deliv Rev 2002; 54:1245-56.
10. Ariyoshi N, Miyamoto M, Umetsu Y, Kunitoh H, Dosaka-Akita H, Sawamura Y, et al. Genetic polymorphism of CYP2A6 gene and tobacco-induced lung cancer risk in male smokers. Cancer Epidemiol Biomarkers Prev 2002; 11:890-4.
11. Tyndale RF, Sellers EM. Genetic variation in CYP2A6-mediated nicotine metabolism alters smoking behavior. Ther Drug Monit 2002; 24:163-71.
12. London SJ, Idle JR, Daly AK, Coetzee GA. Genetic variation of CYP2A6, smoking, and risk of cancer. Lancet 1999; 353(9156):898-9.
13. Tricker AR. Nicotine metabolism, human drug metabolism polymorphisms, and smoking behaviour. Toxicology 2003; 183:151-73.
14. Kamataki T, Nunoya K, Sakai Y, Kushida H, Fujita K. Genetic polymorphism of CYP2A6 in relation to cancer. Mutat Res 1999; 428:125-30.
15. Tan W, Chen GF, Xing DY, Song CY, Kadlubar FF, Lin DX. Frequency of CYP2A6 gene deletion and its relation to risk of lung and esophageal cancer in the Chinese population. Int J Cancer 2001; 95:96-101.
16. Godoy W, Albano RM, Moraes EG, Pinho PR, Nunes RA, Saito EH, et al. CYP2A6/2A7 and CYP2E1 expression in human oesophageal mucosa: regional and inter-individual variation in expression and relevance to nitrosamine metabolism. Carcinogenesis 2002; 23:611-6.
17. Sachse C, Smith G, Wilkie MJ, Barrett JH, Waxman R, Sullivan F, et al. A pharmacogenetic study to investigate the role of dietary carcinogens in the etiology of colorectal cancer. Carcinogenesis 2002; 23:1839-49.
18. Nowell S, Coles B, Sinha R, MacLeod S, Luke Ratnasinghe D, Stotts C, et al. Analysis of total meat intake and exposure to individual heterocyclic amines in a case-control study of colorectal cancer: contribution of metabolic variation to risk. Mutat Res 2002; 506-507:175-85.
19. Nowell S, Sweeney C, Hammons G, Kadlubar FF, Lang NP. CYP2A6 activity determined by caffeine phenotyping: association with colorectal cancer risk. Cancer Epidemiol Biomarkers Prev 2002; 11:377-83.
20. Sweeney C, Coles BF, Nowell S, Lang NP, Kadlubar FF. Novel markers of susceptibility to carcinogens in diet: associations with colorectal cancer. Toxicology 2002; 181-182:83-7.
21. Gross M, Kruisselbrink T, Anderson K, Lang N, McGovern P, Delongchamp R, Kadlubar F. Distribution and concordance of N-acetyltransferase genotype and phenotype in an American population. Cancer Epidemiol Biomarkers Prev 1999; 8:683-92.
22. Xu P, Huang SL, Zhu RH, Han XM, Zhou HH. Phenotypic polymorphism of CYP2A6 activity in a Chinese population. Eur J Clin Pharmacol 2002; 58:333-7.
23. Saruwatari J, Nakagawa K, Shindo J, Tajiri T, Fujieda M, Yamazaki H, et al. A population phenotyping study of three drug-metabolizing enzymes in Kyushu, Japan, with use of the caffeine test. Clin Pharmacol Ther 2002; 72:200-8.
24. Bechtel YC, Haffen E, Lelouët H, Brientini MP, Paintaud G, Miguet JP, Bechtel PR. Relationship between the severity of alcoholic liver cirrhosis and the metabolism of caffeine in 226 patients. Int J Clin Pharmacol Ther 2000; 38:467-75.
25. Bechtel YC, Lelouët H, Brientini MP, David-Laroche M, Miguet JP, et al. Caffeine metabolism differences in acute hepatitis of viral and drug origin. Therapie 2000; 55:619-27.
26. Anderson KE, Kadlubar FF, Kulldorff M, Harnack L, Gross M, Lang NP, et al. Dietary intake of heterocyclic amines and benzo(a)pyrene: associations with pancreatic cancer. Cancer Epidemiol Biomarkers Prev 2005; 14:2261-5.
27. Willett WC, Reynolds RD, Cottrell-Hoehner S, Sampson L, Browne ML. Validation of a semi-quantitative food frequency questionnaire: comparison with a 1-year diet record. J Am Diet Assoc 1987; 87:43-7.
28. Butler MA, Lang NP, Young JF, Caporaso NE, Vineis P, Hayes RB, et al. Determination of CYP1A2 and NAT2 phenotypes in human populations by analysis of caffeine urinary metabolites. Pharmacogenetics 1992; 2:116-27.
29. Kapitulnik J, Popper PJ, Conney AH. Comparative metabolism of benzo[a]pyrene and drugs in human liver. Clin Pharmacol Ther 1977; 21:166-76.
30. Le Marchand L, Hankin JH, Wilkens LR, Pierce LM, Franke A, Kolonel LN, et al. Combined effects of well-done red meat, smoking, and rapid N-acetyltransferase 2 and CYP1A2 phenotypes in increasing colorectal cancer risk. Cancer Epidemiol Biomarkers Prev 2001; 10:1259-66.
31. Sesardic D, Boobis AR, Edwards RJ, Davies DS. A form of cytochrome P450 in man, orthologous to form d in the rat, catalyses the O-deethylation of phenacetin and is inducible by cigarette smoking. Br J Clin Pharmacol 1988; 26:363-72.
32. Goodz SD, Tyndale RF. Genotyping human CYP2A6 variants. Methods Enzymol 2002; 357:59-69.
33. Bourian M, Gullstén H, Legrum W. Genetic polymorphism of CYP2A6 in the German population. Toxicology 2000; 144:129-37.
34. Ahijevych KL, Tyndale RF, Dhatt RK, Weed HG, Browning KK. Factors influencing cotinine half-life during smoking abstinence in African American and Caucasian women. Nicotine Tob Res 2002; 4:423-31.
35. Paschke T, Riefler M, Schuler-Metz A, Wolz L, Scherer G, McBride CM, Bepler G. Comparison of cytochrome P450 2A6 polymorphism frequencies in Caucasians and African-Americans using a new one-step PCR-RFLP genotyping method. Toxicology 2001; 168:259-68.
36. Oscarson M, McLellan RA, Gullstén H, Yue QY, Lang MA, Bernal ML, et al. Characterisation and PCR-based detection of a CYP2A6 gene deletion found at a high frequency in a Chinese population. FEBS Lett 1999; 448:105-10.
37. Loriot MA, Rebuissou S, Oscarson M, Cenée S, Miyamoto M, Ariyoshi N, et al. Genetic polymorphisms of cytochrome P450 2A6 in a case-control study on lung cancer in a French population. Pharmacogenetics 2001; 11:39-44.
38. Topcu Z, Chiba I, Fujieda M, Shibata T, Ariyoshi N, Yamazaki H, et al. CYP2A6 gene deletion reduces oral cancer risk in betel quid chewers in Sri Lanka. Carcinogenesis 2002; 23:595-8.
39. Tsukino H, Kuroda Y, Qiu D, Nakao H, Imai H, Katoh T. Effects of cytochrome P450 (CYP) 2A6 gene deletion and CYP2E1 genotypes on gastric adenocarcinoma. Int J Cancer 2002; 100:425-8.
40. Guengerich FP, Shimada T, Yun CH, Yamazaki H, Raney KD, Thier R, et al. Interactions of ingested food, beverage, and tobacco components involving human cytochrome P4501A2, 2A6, 2E1, and 3A4 enzymes. Environ Health Perspect 1994; 102(Suppl 9):49-53.
41. Hecht SS, Carmella SG, Foiles PG, Murphy SE, Peterson LA. Tobacco-specific nitrosamine adducts: studies in laboratory animals and humans. Environ Health Perspect 1993; 99:57-63.
42. Pianezza ML, Sellers EM, Tyndale RF. Nicotine metabolism defect reduces smoking. Nature 1998; 393(6687):750.
43. Ando M, Hamajima N, Ariyoshi N, Kamataki T, Matsuo K, Ohno Y. Association of CYP2A6 gene deletion with cigarette smoking status in Japanese adults. J Epidemiol 2003; 13:176-81.
44. Kirby GM, Batist G, Alpert L, Lamoureux E, Cameron RG, Alaoui-Jamali MA. Overexpression of cytochrome P-450 isoforms involved in aflatoxin B1 bioactivation in human liver with cirrhosis and hepatitis. Toxicol Pathol 1996; 24:458-67.
45. Raunio H, Juvonen R, Pasanen M, Pelkonen O, Pääkkö P, Soini Y. Cytochrome P4502A6 (CYP2A6) expression in human hepatocellular carcinoma. Hepatology 1998; 27:427-32.